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Abstract
We hypothesized that administration of the superoxide dismutase (SOD) mimetic Tempol (4-
hydroxy-2, 2, 6, 6-tetramethylpiperidine 1-oxyl) may reverse diabetes induced ED(erectile 
dysfunction). To test this hypothesis, ROS related genes (SOD1, SOD2, GPx1, CAT, NOS2, 
NOS3), erectile functional studies, and immunohistochemical analysis were performed in diabetic 
rats treated with or without Tempol. Thirty Sprague-Dawley (3–4 months old) rats were divided 
into 3 groups (n=10 each), 20 with diabetes (diabetic control and Tempol treatment) and 10 
healthy controls. Twelve weeks after induction of diabetes by streptozotocin and Tempol 
treatment, all groups underwent in vivo cavernous nerve stimulation. Rat crura were harvested and 
expression of antioxidative defense enzymes examined by semi-quantitative RT-PCR. To confirm 
the RT-PCR results, we performed immunohistochemistry (IHC) for catalase (CAT) and iNOS 
(NOS2). Nitration of tyrosine groups in proteins was also examined by IHC. Mean intracavernous 
pressure in the diabetic group was significantly lower than in healthy controls (p<0.001) and was 
reversed by Tempol treatment (p<0.0108). NOS2 protein expression was significantly increased in 
diabetic animals compared to healthy controls and Tempol restored NOS2 protein level. 
Nitrotyrosine was also higher in diabetic animals and though Tempol treatment decreased its 
formation, it remained higher than that found in healthy controls. This study suggests that Tempol 
treatment increased erectile function through modulating oxidative stress related genes in diabetic 
rats. This is the first report about the relationship between diabetes induced erectile dysfunction 
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
**To whom correspondence should be addressed: Rajvir Dahiya, Ph.D., Professor and Director, Urology Research Center (112F), 
Veterans Affairs Medical Center and University of California at San Francisco, 4150 Clement Street, San Francisco, CA 94121, 
Phone: 415-750-6964; Fax: 415-750-6639; rdahiya@urology.ucsf.edu. 
Conflict of interest
None declared.
HHS Public Access
Author manuscript
Int J Impot Res. Author manuscript; available in PMC 2014 March 03.
Published in final edited form as:
Int J Impot Res. 2009 ; 21(6): 348–355. doi:10.1038/ijir.2009.28.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
and oxidative stress, and anti-oxidative therapy using the superoxide dismutase mimetic, Tempol 
to restore erectile function.
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INTRODUCTION
There are 23.6 million children and adults in the United States, or 7.8% of the population, 
who have diabetes. While an estimated 17.9 million have been diagnosed with diabetes, 5.7 
million people (or nearly one quarter) are unaware that they have the disease. 1 It has been 
estimated that 50% to 75% of males with diabetes have erectile dysfunction (ED).2 In men, 
ED is one of the major complications of diabetes.
The penis is a richly vascularized organ, and penile erection is, in large part, a vascular 
event. Recent reports show that in men with diabetes mellitus, erectile dysfunction is an 
early event and a potential marker for cardiovascular disease.3 Data from several studies 
involving diabetic patients with cardiac disease have shown a high prevalence (42% to 75%) 
of ED in the patient population. Also a recent report showed incidence rates of occult 
cardiovascular disease in men with ED as high as 15% to 30%.4 Therefore ED is considered 
to be an early manifestation of systemic endothelial dysfunction.
The cause of diabetes-induced ED is multifactorial and its mechanisms are not fully 
understood. The first line treatment, phosphodiesterase type 5 inhibitor (e.g., Sildenafil, 
Vardenafil and Tadalafil) is widely used as a medicine to maintain an erection, but in 
diabetes its effect is clearly reduced when compared with non-diabetic men.5 Oxidative 
stress occurs when reactive oxygen and nitrogen species (ROS and RNS, respectively) 
production is excessive and/or defense mechanisms fail. ROS are kept under control by an 
endogenous system of protection that consists of scavenger enzymes (superoxide dismutase, 
catalase, glutathione peroxidase) and antioxidants (vitamin E, beta-carotene, ascorbic acid, 
glutathione).
A number of sources of ROS, in particular superoxide anion, have been identified in 
diabetes including non-enzymatic, e.g. mitochondrial respiratory chain, glucose 
autoxidation, activation of polyol pathways, glycation-formation of AGEs (advanced 
glycation end products) and enzymatic, e.g. NAD(P)H oxidase, uncoupled eNOS, xanthine 
oxydase, cyclooxygenase.6 It has been shown that oxidative damage due to hyperglycemia 
contributes to both macro and microvascular pathology in diabetes such as atherosclerosis, 
cardiovascular diseases, retinopathy, nephropathy and peripheral neuropathy.7 A recent 
publication has suggested that there is a close relationship between oxidative stress and 
diabetic ED in both animal models and humans.8
Natural anti-oxidants, in particular vitamin E, have demonstrated little beneficial effect in 
clinical trials.9 It has recently been suggested that antioxidant therapy with vitamin E or 
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others is limited to scavenging already formed oxidants, particularly lipid peroxidation 
products. 10
Tempol (4-hydroxy-2, 2, 6, 6-tetramethylpiperidine 1-oxyl), is a low molecular weight, 
water-soluble, membrane permeable and metal-independent superoxide dismutase (SOD) 
mimetic, which has been widely employed in electron spin resonance spectroscopy.11 
Tempol can penetrate cell membranes and react with both intra- and extra-cellular oxygen 
free radicals, resulting in protecting endothelial function. 12
This property makes Tempol attractive for treatment of diseases related to oxidative stress. 
Recent studies have indicated that Tempol can be used as an antioxidant in animal models to 
prevent many diseases that are caused by ROS such as ischemic-reperfusion injury, 
inflammation and shock.13
However in most of these experiments, Tempol has been administered before or at the time 
of onset of disease. Diabetes mellitus, a continuous hyperglycemia, is a chronic disease, 
therefore its complications are already established at the time of diagnosis. Our aim in this 
study was to assess whether delayed and chronic administration of an anti-oxidant 
superoxide scavenger such as Tempol would be effective as an intervention to diabetic ED 
complications. To our knowledge there have been no reports about Tempol, ROS and its 
effect on ED.
MATERIAL AND METHODS
Experimental animals
Thirty 3 to 4 month-old (440–560mg) male Sprague-Dawley rats (Charles River 
Laboratories, Wilmington, Massachusetts) were divided into the following 3 groups: (1) 
healthy controls, (2) diabetes untreated, (3) diabetes antioxidant (Tempol) treated. The 
diabetic group received two intraperitoneal injections of 40 mg/kg storeptozotocin (STZ) 
(Sigma-Aldrich, Inc., St Louis, Missouri) at 1-week intervals to induce diabetes. STZ was 
dissolved in citrate phosphate buffer (0.1M citric acid and 0.2M disodium phosphate, pH 
7.0). Control rats were injected with an equal volume of buffer only (Fig. 1). The 
development of diabetes was confirmed by blood glucose levels 1 week after STZ injection. 
STZ treated rats with a blood glucose level of below 250 mg/dl were excluded from this 
study. Body weight and blood glucose levels in serum samples obtained from the tail vein 
were measured weekly. Tempol treatment was started 6 weeks after the establishment of 
diabetes. Subcutaneous injections of 100 mg/kg Tempol (4-hydroxy-2, 2, 6, 6-
tetramethylpiperidine 1-oxyl) (Sigma-Aldrich, Inc., St Louis, Missouri) were administered 
twice a day for 6 weeks.
This project was approved by the animal ethics committee (project number; A3476-01).
Functional study
Erectile function was assessed by measurement of intracavernous pressure after electro 
stimulation of the cavernous nerve.14, 15 Briefly, after anesthesia by inhalation of 
sevoflurane (Baxter Healthcare Corporation, Deerfield, Illinois), rats were placed in a supine 
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position and through a low abdominal midline incision the lateral prostatic space was 
exposed on each side. The major pelvic ganglia, pelvic nerves and cavernous nerves were 
identified and exposed. The skin overlying the penis was incised and the penile crura were 
exposed by removing part of ischiocavernous muscle and fascia. A 23 gauge needle filled 
with 250 U/ml heparin solution was inserted into the crura and connected to a pressure 
monitor with polyethylene tubing. The increase in intracavernous pressure was measured 
and recorded using LabVIEW 5.0 (National Instruments, Austin, Texas) software. Electro 
stimulation was performed with a delicate stainless steel bipolar hook electrode and 
monophasic rectangular voltage pulses were delivered using a computer program. The 
stimulus parameters were 1.5 mA, 20 Hz frequency, pulse width 0.2 millisecond and a 
duration of 60 seconds. The cavernous nerve was stimulated 5 times at 4-minutes interval on 
each side. ICP was measured and recorded with Lab View 5.01 software (National 
Instruments, Austin, Texas). The ICP is defined as the maximal pressure obtained by 
stimulation minus the basal pressure before stimulation. The latency period is defined as the 
time between cavernous nerve stimulation and the onset of pressure rise inside the penile 
crura.
After the functional study was completed a crura was obtained and incubated in RNAlater 
RNA Stabilization Reagent (QIAGEN Inc., Valencia, California) overnight at 4C and the 
next day the samples were frozen in liquid nitrogen and stored at −80°C until processed for 
mRNA expression analysis. The crura of the other side was placed in a 4% formaldehyde 
solution for immunohistochemical studies of cavernous tissue. After the procedure the rats 
were sacrificed by thoracotomy.
RNA isolation
Total RNA was isolated using a combination of TRIzol Reagent (Invitrogen, Carlsbad, 
California) and RNeasy Mini Kit(QIAGEN Inc., Valencia, California), as described 
previously.16 Tissue was homogenized in TRIzol reagent, chloroform was added and 
centrifugation performed to improve recovery of the aqueous phase of the solution. Ethanol 
(100%) was added to an equal volume of the recovered aqueous solution, and the mixture 
was added to an RNeasy minicolumn. All subsequent steps were performed as described by 
the supplier (QIAGEN RNeasy Mini hand book Third Edition). The concentration and 
quality of RNA was measured by spectrophotometric analysis at 260 and 280 nm.
Reverse transcriptase Polymerase chain reaction (RT-PCR)
Total RNA was reverse transcribed into cDNA with the use of Reverse Transcription 
System (Promega Corporation, Madison, Wisconsin) using oligo(dT) as primers. 
Antioxidative enzyme, such as Cu/ZnSOD (SOD1), MnSOD (SOD2), Glutathione 
peroxidase (GPx1) and catalase (CAT), and also nitric oxide synthase, inducible (iNOS; 
NOS2) and endothelial (eNOS; NOS3) were analyzed by a semi-quantitative method. 
Primer sets used for RT-PCR are shown in Table 1. PCR cycle parameters consisted of a 1 
minute denaturing step at 94C, 1 minute annealing step at 58C, 1 minute extension step at 
72C and 40 cycles were used per amplification. Beta-Actin served as an internal control. 
The expression of SOD1, SOD2, GPx1, CAT, NOS2 and NOS3 relative to Beta-Actin was 
quantified by densitometry.
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Immunohistochemistry
Immunostaining was performed on formalin fixed, paraffin embedded rat crura tissue 
sections. Five μm sections were deparaffinized with xylene and rehydrated in graded 
alcohols followed by rinsing with distilled water. Antigen retrieval was carried out by 
autoclaving the slides in 10mM sodium citrate buffer (pH 6.0). Endogenous peroxidase 
activity was blocked with 3% H2O2. Incubation with goat anti-rabbit serum (Santa Cruz 
Biotechnology, Santa Cruz, California) was used to block non-specific protein binding. The 
nitrotyrosine antibody (Rabbit polyclonal IgG, cat# 06-284, Upstate Cell Signaling 
solutions, Lake Placid, New York) was diluted to 2.5 μg/ml and incubated with slides 
overnight. To confirm the RT-PCR results, we performed IHC for catalase (CAT) 
(#ab52477, Abcam, Cambridge, MA) and iNOS (NOS2) (#53584, Anaspec, San Jose, CA). 
Omitting the primary antibody was used as negative control. Slides were then incubated 
with biotinylated secondary antibody to IgG (Santa Cruz Biotechnology, Santa Cruz, 
California). After washing, the slides were next incubated with HRP-streptavidin (Santa 
Cruz Biotechnology, Santa Cruz, California), washed and stained with diaminobenzidine 
(LAB Vision Corporation, Fremont, California) and counterstained with hematoxylin.
Statistics
All data are expressed as the mean ± SE and were analyzed using ANOVA with Bonferroni/
Dunn post hoc test for multiple group comparisons on Statview 5. 0. 1 (SAS Institute, Cary, 
North Carolina).
RESULTS
Development of diabetes
At 12 weeks after STZ injections diabetic rats (diabetic control and Tempol treatment) were 
significantly lighter in body weight than age matched healthy controls (452.0 ± 6.6, 448.6 ± 
21.8 vs 603.6 ± 11.8 gm, p < 0.05) and had higher levels of blood glucose (361.8± 18.2, 
368.7 ± 19.7 vs 109.4 ±4.0 mg/dl, p < 0.05). They also showed the usual signs of diabetes, 
such as polydipsia and polyuria. In diabetic rats, Tempol injections did not have a significant 
impact on body weight or on blood glucose levels.
Erectile function
Fig. 1 shows erectile function in diabetic, healthy control and Tempol treated rats. Maximam 
intracavernous pressure in diabetes was generally lower compared to that observed in 
healthy controls (78.8 ± 5.6 vs 130.5 ± 4.8 cm H2O, p< 0.05). In addition the pressure was 
not maintained and declined even further with time. Tempol treatment partially restored 
intracavernous pressure in diabetic ED (101.7 ± 5.6 vs 78.8 ± 5.6 cm H2O, p< 0.05). 
Tempol treatment reversed about 44.3% of the diabetes-induced reduction in intracavernous 
pressure.
RT-PCR analysis
Figure 2 shows the relative levels of SOD1, SOD2, GPx1, CAT, NOS2 and NOS3 mRNA 
transcripts in the penile rat crura. SOD2 mRNA expression was significantly lower in 
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diabetic rats compared to healthy controls (Fig 3-B). Tempol treated diabetic rats had 
increased mean levels of SOD2 mRNA expression. CAT mRNA expression in diabetic rats 
was significantly lower compared to healthy controls (Fig 3-D). Tempol treated animals had 
CAT mRNA levels similar to those in healthy controls. NOS2 (iNOS) mRNA expression in 
diabetic rats was significantly higher compared to healthy controls (Fig 3-E). Tempol treated 
rats had NOS2 mRNA levels lower than that of healthy controls.
SOD1, GPx1 and NOS3 mRNA expression did not significantly change among diabetic 
animals, healthy controls and the Tempol treated group (Fig 3-A, C, F).
Immunohistochemistry of rat crura
To confirm the RT-PCR results, we performed IHC for catalase (CAT) and NOS2 (iNOS). 
We did not find a significant difference in CAT expression between DM and the Tempol 
treatment group (data not shown). However NOS2 protein levels were dramatically 
decreased in the Tempol treated group and this result was similar to the RT-PCR results. 
Typical NOS2 (iNOS) immunostaining is shown in Fig. 4.
NOS2 (iNOS) was stained in penile cavernosal smooth muscle and endothelium. Fig. 5 
shows that nitrotyrosine protein expression in the artery wall and smooth muscle cells was 
higher in diabetic rats than in healthy controls. Tempol treatment decreased nitrotyrosine 
formation but not to healthy control levels.
Discussion
This is the first report to demonstrate the relationship between diabetes induced erectile 
dysfunction, oxidative stress, and anti-oxidative therapy using the superoxide dismutase 
mimetic, Tempol, to restore erectile function. Diabetic erectile dysfunction invilves several 
factors including NO, ROS, NOS (NOS1, NOS2, and NOS3), peroxynitrite, and others. 
Nitric oxide (NO), a vasodilator, is a principal mediator in the initiation and maintenance of 
penile erection. NO production plays a central role in modulating endothelial function.17 
Decreased relaxation of the cavernosal tissue in experimental diabetic animals is associated 
with a lack of NO bioavailability.18 Vascular endothelial cells are an important target of 
hyperglycemic damage. It has been shown that hyperglycemia increases the production of 
ROS inside cultured bovine aortic endothelial cells.19 A recent study demonstrated that the 
hyperglycemia induced process of overproduction of superoxide at the mitochondrial level, 
is the initial and key event in the activation of all other pathways involved in the 
pathogenesis of diabetic complications.20 Hyperglycemia also favors increased expression 
of iNOS (NOS2) through the activation of stress sensitive pathways such as NFκB which 
can increase the generation of NO.21 Superoxide immediately interacts with NO, generating 
cytotoxic peroxynitrite (ONOO-), thereby reducing the efficacy of the potent endothelium 
derived vasodilator system that participates in the homeostatic regulation of the vasculature. 
Peroxynitrite, a potent oxidative stress inducer, leads to the iNOS (NOS2) and eNOS 
(NOS3) uncoupled state, due to a deficiency of tetrahydrobiopterin (BH4), a NOS cofactor, 
resulting in the production of superoxide rather than NO.7 It has also been shown that 
peroxynitrite induces nitrotyrosine formation, lipid peroxidation, DNA strand breakage and 
consequent activation of the nuclear enzyme poly (ADP-ribose) polymerase (PARP). PARP 
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activation in turn depletes the intracellular concentration of its substrate NAD+, slowing the 
rate of glycolysis, electron transport, and ATP formation, and produces the ADP-
rybosylation of GADPH, resulting in endothelial dysfunction.22
Based on this evidence, we examined the mRNA and protein levels of antioxidative 
enzymes in control, diabetes, and Tempol treated rats to confirm the effect of Tempol on rat 
crura.
We observed decreased catalase (CAT) mRNA expression in diabetes but there was no 
change in CAT protein levels between control and diabetes. We did not examine CAT 
activity however our results may suggest that Tempol does not affect CAT expression. In 
our study, NOS2 (iNOS) mRNA and protein levels increased in diabetic rats and this result 
is consistent with a previous report.23 Also, the protein expression level of iNOS (NOS2) 
was restored in Tempol treated rats. We also found higher nitrotyrosine protein expression 
in diabetic rats in the artery wall and smooth muscle cells with decreased nitrotyrosine 
protein levels in Tempol treated rats. However it is unknown why Tempol affected 
peroxynitrite expression levels. Additonal studies are needed to address this. Under potent 
oxidative stress conditions such as diabetes, peroxynitrite induces NOS2 (iNOS) and 
nitrotrysine in various tissues. 24–26 Nitrotyrosine formation mediates apoptosis and 
pathological angiogenesis in endothelial cells.27–29
A previous report from our laboratory suggested that diabetic rats have enhanced apoptotic 
activity in rat crura.30 In this study we did not perform apoptosis analysis in Tempol treated 
rats crura. However, our results showing that hyperglycemia induced nitrotyrosine formation 
and NOS2 production suggest that there may be increased apoptosis in diabetic rat crura. 
Thus Tempol might inhibit apoptosis in diabetic rat crura and restore endothelial function.
In this study Tempol treatment was started at 6 weeks after the onset of diabetes. Our 
previous results have indicated that low intracavernous pressure was observed 4 weeks after 
the onset of diabetes.30 Since diabetes is a chronic disease, Tempol was administered to rats 
with established diabetic induced ED. The delayed and continuous Tempol treatment 
regimen used in this study partially restored erectile function but we hypothesize that if 
Tempol was administered before or at the onset of diabetes, its effect might be more 
dramatic.
In conclusion, the administration of Tempol to diabetic rats inhibited superoxide 
overproduction. It also reversed the increase of iNOS mRNA expression in rat crura and 
release of nitric oxide from endothelial cells leading to decreased formation of peroxynitrite. 
In addition, decreased peroxynitrite lead to functional restoration of endothelial cells and in 
turn erectile function. Suppression of oxidative stress is potentially a new strategy for 
treating diabetes induced erectile dysfunction.
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Figure 1. 
Intracavernous pressure, Mean maximum pressure in DM was significantly lower than 
healthy control’s. Tempol treatment partially restored in the cavernous pressure.
Note; *Healty control vs DM, p<0.0001; * * DM vs Tempol treatment, p<0.01
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Figure 2. 
SOD1, SOD2, GPx1, CAT, NOS2 and NOS3 mRNA expression in penile rat crura from 
healthy control, diabetic controls and following Tempol treatment.
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Figure 3. 
Mean quantitative gene expression of SOD1 (A), SOD2 (B), GPx1 (C), CAT (D), NOS2 (E) 
and NOS3 (F) was analyzed using densitometry. In SOD1 mRNA expression there was no 
significant change among healthy controls, DM controls and the Tempol treatment group. 
However SOD2 mRNA expression in DM was significantly lower than healthy control’s 
and Tempol treatment partially restored its expression but did not reach significance. 
Glutathione peroxidase (GPX1) mRNA expression (C) was similar in all groups. CAT 
mRNA expression (D) in DM was significantly lower than in healthy controls and Tempol 
treatment restored CAT to healthy control level. NOS2 mRNA expression (E) in DM was 
significantly higher than healthy controls and Tempol treatment mRNA was lower than 
healthy controls. In NOS3 mRNA expression (F) there was no significant change among 
diabetes, healthy control and Tempol treatment group.
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Figure 4. 
Representative immunohistochemical staining of rat corpus cavernosum of NOS2 (iNOS). 
Smooth muscle and endothelium are stained brown in diabetic rats. Magnification is x100.
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Figure 5. 
Immunohistochemistry of anti-nitrotyrosine. Nitrotyrosine protein expression in artery wall 
and smooth muscle cells of rat crura was higher in diabetic rats than in healthy controls. 
Tempol treatment decreased nitrotyrosine formation. Magnification is x200.
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Table 1
RT-PCR primers
Primer Sequence 5′→3′ Product size Accession number
SOD1: Forward CGT CAT TCA CTT CGA GCA GA 401bp NM 017050
Reverse CAA TCA CAC CAC AAG CCA AG
SOD2: Forward TGA CCT GCC TTA CGA CTA TGG 533bp NM 017051
Reverse CAT TCC AAA TGG CTT TCA GA
GPx1: Forward GTT TCC CGT GCA ATC AGT TC 371bp NM 030826
Reverse CTT GGA CAG CAG GGC TTC TA
CAT: Forward TTG GCC TCA CAA GGA CTA CC 495bp NM 012520
Reverse AGG TGG TTG GCA ATG TTC TC
NOS2: Forward GCT CCA TGA CTC TCA GCA CA 409bp NM 012611
Reverse AAA AGA CCG CAC CGA AGA TA
NOS3: Forward GCC CCG GTA CTA CTC TGT CA 476bp NM 021838
Reverse CTG TCC TCA GGA GGT CTT GC
β-actin: Forward AGC CAT GTA CGT AGC CAT CC 411bp NM031144
Reverse AGG AAG GAA GGC TGG AAG AG
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